Enrollees in silver plans through the exchanges could be paying more than twice as much on prescription drugs than they would under a typical employer plan, new research finds.
The report — commissioned by the Pharmaceutical Research and Manufacturers of America and conducted by actuarial firm Milliman — found exchange participants are paying a "far larger increase in out-of-pocket costs than was found for other medical care."
Overall, the report found that silver plan enrollees would likely pay 130 percent more for out-of-pocket prescription drugs compared to people on similar employer-sponsored plans.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.